In May 2011, Roche and MSD (known as Merck in the US) struck a deal to co-promote Victrelis, Merck’s new treatment for chronic hepatitis C. More unusually, the two companies also agreed to pool ...

Early prescription data show doctors' preference for Vertex's Hep C drug Incivek over a rival drug from Merck launched at the same time. in May just 10 days apart, which means Vertex and Merck ...

Most DAAs are only available as part of a combination pill. The first-generation hepatitis C protease inhibitors, boceprevir (Victrelis) and telaprevir (Incivo), were approved in 2011. They were only ...

George Njoroge -- a renowned Kenyan researcher who in 2011 discovered Victrelis, the first oral protease inhibitor that cured Hepatitis C -- is behind the plan. Under the plan, a team of experts ...